When the time comes, you'll be judged for your actions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
stop loss still intact?
When the Mayo Clinic are onboard then you know you have backed a winner.
We are preparing the submission to the Mayo Clinic
Independent Review Board and will be able to submit it
promptly subject to receipt of the IDE clearance from the
FDA.
*We repeated the training certification of the Mayo Clinic
therapist to demonstrate improved processes and
procedures.
*Two other Mayo lung cancer doctors attended the training
since they are interested, subject to FDA clearance, in
eventually using RadioGel® to treat lung cancer.
FDA approval right around the corner!!
Worlds best trader hold shares when they think the price is going down. Totally believable.
www.isopet.com is back online.
they had 1.7million cash end of Jun
Let's say max 10k a month for the isopet van.
I think they will be ok
They have an offering out, there can't be a private placement lined up.
Nice try on both counts
Betaglue had to go to Georgia as they couldn't start clinical trials where it matters, the US. They could have tried the EU but I guess that was too hard for them too
Betaglue leaves permanent microspheres in the body, it's just a delivery method for existing tech.
It's strange that there are no true competitors to Radiogel 2 years after the Battelle patents expired. Having read the patents I know why but you keep up with the lies and we will check back in a few years and see there are still no competitors as Radiogel's patents protect their tech.
Don't confuse yourself
Isopet is profitable..truth hurts grasshopper
Another whopper of a lie
They made a 20% profit on Isopet in Q2
Once it scales those margins will improve.
What a whopper of a lie even for your standards.
TheraSphere microspheres are made of a glass matrix that is non-biodegradable. Once these microspheres are injected into the liver’s blood vessels, they remain lodged in the vasculature of the tumor, delivering radiation directly to the cancer cells. The glass itself does not break down or get absorbed by the body.
Long-term Presence: The microspheres are designed to stay in place permanently. The glass microspheres remain inert within the body.
Here is a summary from Boston Scientific on the nature of TheraSphere microspheres:
Durability: "TheraSphere microspheres are biologically inert, permanent implants designed to provide a sustained delivery of radiation to liver tumors."
Retention: "The microspheres remain within the blood vessels of the liver tumor"
Conclusion
The statement that "amorphous silicates like glass are broken down and eliminated from the body without issue" does not hold true in the context glass microspheres.
The market is highly responsive to the CEO buying more shares, interpreting it as a strong signal of confidence in the company’s future.
While IDE approval is important, the market also values the CEO’s commitment to the company, and this action positively influences market sentiment. In this case, I share the market's appreciation for the CEO’s proactive approach.
All of the planned expenditures on the animal market are essential and well-justified investments of time and money.
The CEO is actively working to develop a business plan that demonstrates how IsoPet will generate significant revenues and is determined to ensure that this division of the business becomes a major revenue driver.
He might owe it to shareholders but not to you
It is what is
Glass beads are in patience for life Very difficult to get all glass out. So most are left in patient.
It is what it is
A strong patent for making the radiogel is already approved, preventing others from making it. Additionally, there is clear evidence of significant performance advantages with MK's process improvements. Radiogel is not public domain and remains protected by these advancements.
It is what it is
A dead tumor is not just a dead tumor—there is significant evidence that Y90 particles dispersed in a solidifying gel are superior to Y90 beads in achieving this outcome. Claims that one method is better than the other are well-substantiated, and the FDA is likely to recognize these distinctions. MK has clearly learned from past experiences and continues to make accurate and informed statements.
A strong patent for making the radiogel is already approved, preventing others from making it. Additionally, there is clear evidence of significant performance advantages with MK's process improvements. Radiogel is not public domain and remains protected by these advancements.
A dead tumor is not just a dead tumor—there is significant evidence that Y90 particles dispersed in a solidifying gel are superior to Y90 beads in achieving this outcome. Claims that one method is better than the other are well-substantiated, and the FDA is likely to recognize these distinctions. MK has clearly learned from past experiences and continues to make accurate and informed statements.
There is substantial evidence that freely dispersed Y90 particles in gel, as used in RDGL, offer performance advantages compared to microbeads dispersed in gel, as seen in Betaglue. A comparative controlled clinical trial is unnecessary to prove this, and RDGL has already applied for clinical trials (a withdrawn application does count).
Additionally, the Radiogel patents are still valid. Betaglue is not free to make the same gel RDGL uses, as Radiogel is not public domain
Rebecca Krimins who carried out the rabbit tests at Johns Hopkins is presenting an abstract which shows no containment issues
We're blessed with the world's traders
Calling for 5 cents when the price was 8 cents and somehow you miraculously held some imaginary shares and sold at 20 cents.
Can't believe the drivel that's comes out of their mouths
Great call grasshopper
Calling for 5 cents when the price was 8 cents and somehow you miraculously held some imaginary shares and sold at 20 cents.
Look what the cat dragged in, and now the coordinated effort to sow doubt. Hilarious
Never quite had the guts to say they are lying in their SEC filings about the BDD. Shame no cohones
After providing addition information to the FDA on December 18, 2023, the FDA classified us as a Breakthrough device to our proposed Indication for Use.